Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Dev Immunol ; 2010: 473453, 2010.
Article in English | MEDLINE | ID: mdl-21253471

ABSTRACT

Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P = .02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.


Subject(s)
Cancer Vaccines/immunology , Peptide Fragments/immunology , Peptides/immunology , Prostate-Specific Antigen/immunology , Prostatic Neoplasms/therapy , Aged , Cancer Vaccines/administration & dosage , Cancer Vaccines/adverse effects , HLA-A2 Antigen/metabolism , Hormones/immunology , Humans , Hypersensitivity, Delayed/immunology , Interferon-gamma/biosynthesis , Male , Middle Aged , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Peptide Fragments/chemistry , Peptides/administration & dosage , Peptides/adverse effects , Peptides/chemistry , Prostate-Specific Antigen/administration & dosage , Prostate-Specific Antigen/adverse effects , Prostate-Specific Antigen/chemistry , Prostatic Neoplasms/immunology , Prostatic Neoplasms/mortality , Risk Factors , Vaccination
2.
Cancer Immunol Immunother ; 55(9): 1033-42, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16283303

ABSTRACT

T cell immunotherapy of prostate cancer (CaP) offers the potential for less toxic, more effective outcomes. A clinical trial was conducted in 28 patients with locally advanced or metastatic CaP to determine whether an HLA-A2 binding epitope of prostate-specific antigen, PSA146-154 (PSA-peptide), can induce specific T cell immunity. Patients were vaccinated either by intradermal injection of PSA-peptide and GM-CSF or by intravenous administration of autologous dendritic cells pulsed with PSA-peptide at weeks 1, 4 and 10. Delayed-type hypersensitivity (DTH) skin testing was performed at weeks 4, 14, 26 and 52. Fifty percent of the patients developed positive DTH responses to PSA-peptide. The size of the DTH induration progressively increased over time in the majority of responding patients. Skin biopsies from seven DTH-positive patients were available and T cells that developed in situ were also characterized. The phenotype of recovered T cells demonstrated variable proportions of CD4+CD8-, CD4-CD8+ and CD4+CD8+ T cell populations. Cytokine analysis of PSA-peptide stimulated T cells per bead array assay exhibited specific IFN-gamma and TNF-alpha response in six of seven patients. Specific IL-4 response was observed in five patients, while IL-10 response was detected in one patient. Purified CD4-CD8+ T cells isolated from four patients demonstrated specific cytolytic activity per chromium release assay. In conclusion, immunization with PSA-peptide induced specific T cell immunity in one-half of the patients with locally advanced and hormone-sensitive, metastatic CaP. DTH-derived T cells exhibited PSA-peptide-specific cytolytic activity and predominantly expressed a type-1 cytokine profile.


Subject(s)
Cancer Vaccines/immunology , Hypersensitivity, Delayed/immunology , Immunotherapy, Active/methods , Peptide Fragments/immunology , Peptides/immunology , Prostate-Specific Antigen/immunology , Prostatic Neoplasms/therapy , T-Lymphocytes, Cytotoxic/immunology , Aged , Aged, 80 and over , Amino Acid Sequence , Cancer Vaccines/administration & dosage , Dendritic Cells/cytology , Dendritic Cells/immunology , Dendritic Cells/transplantation , Epitopes , Humans , Immunity, Cellular , Male , Middle Aged , Molecular Sequence Data , Peptide Fragments/administration & dosage , Peptides/administration & dosage , Prostate-Specific Antigen/administration & dosage , Prostatic Neoplasms/immunology , T-Lymphocyte Subsets/immunology , Transplantation, Autologous
3.
Clin Immunol ; 117(1): 94-9, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16027040

ABSTRACT

In this study, we have concurrently assayed for IL-2, IL-4, IL-6, IL-10, TNF-alpha, and IFN-gamma in 24-h serum-free cultures of peripheral blood mononuclear cells (PBMC) obtained from seventeen patients with prostate cancer (CaP) per cytokine bead array analysis. The purpose of the study is to examine the nature of the cytokine profile operating among patients and to correlate with their physical, biochemical, and clinical parameters. Unstimulated PBMC cultures from patients with hormone-sensitive metastatic disease demonstrated elevated level of baseline TNF-alpha compared to patients with high-risk, locally advanced disease. Younger patients exhibited significantly higher levels of IL-4 and TNF-alpha compared to older patients following PHA stimulation. Similarly, significantly higher ratios of IFN-gamma/IL-4, IFN-gamma/IL-10, and IL-2/IL-4, a favorable type-1 cytokine pattern, were observed in patients with lower serum PSA compared to patients with high serum PSA. These results indicate the existence of distinct cytokine patterns among patients with CaP.


Subject(s)
Cytokines/biosynthesis , Leukocytes, Mononuclear/immunology , Prostatic Neoplasms/immunology , Aged , Aged, 80 and over , Cells, Cultured , Cytokines/immunology , Flow Cytometry , Humans , Immunophenotyping , Male , Middle Aged
4.
Cancer Immunol Immunother ; 51(5): 263-70, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12070713

ABSTRACT

Prostate-specific antigen (PSA) is a potentially useful antigen for targeted T-cell immunotherapy of prostate cancer (CaP). Our laboratory has identified a synthetic nonamer peptide (PSA 146-154) homologue of PSA, which binds to the prevalent human leukocyte antigen, HLA-A2, and elicits specific cytotoxic T-lymphocyte (CTL) responses from normal individuals of the HLA-A2 phenotype. In the present study, we report on the induction of CTL from peripheral blood mononuclear cells (PBMC) of patients with hormone-refractory CaP, which exhibit the same specificity. T-cell lines were established from two patients by stimulation of PBMC with PSA 146-154 peptide in vitro. The T-cell lines exhibited specific cytolytic activity against T2 cells pulsed with PSA 146-154 peptide, but not a control HLA-A2 binding peptide (HIV-RT 476-484) via chromium release assay (CRA). The T-cell lines also showed PSA 146-154 peptide-specific IL-4 responses, but no detectable interferon-gamma (IFN-gamma) responses via enzyme-linked immuno-spot assays. Magnetic immuno-selection studies of one of the T-cell lines demonstrated that both cytolytic and interleukin-4 (IL-4) responses were mediated by CD8(+), but not by CD4(+) T cells. This Tc2 line was further characterized for the ability to recognize endogenously processed PSA epitopes. The line specifically secreted IL-4 in response to HLA-A2(+) target cells transfected to express PSA and specifically lysed the PSA(+) target cells, but not control transfected cells. The results indicate that the PSA 146-154 peptide emulates a naturally processed and presented peptide epitope of PSA that is within the T-cell repertoire of HLA-A2(+)patients with CaP.


Subject(s)
Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , T-Lymphocytes, Cytotoxic/metabolism , Aged , Chromium/pharmacology , Cytokines/biosynthesis , Enzyme-Linked Immunosorbent Assay , Epitopes , Flow Cytometry , Humans , Immunotherapy/methods , Interferon-gamma/metabolism , Interleukin-4/metabolism , Male , Peptides/chemistry , Prostate-Specific Antigen/chemistry , Transfection , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...